Reflecting this, epigenetic treatments are now part of the standard of care for several haematological malignancies; DNMT inhibitors are currently used for the treatment of AML and MDS, and HDACs are FDA-approved for the treatment of MM, CTCL, and peripheral T-cell lymphoma [374]. This evidence concerns the gene DNMT1 and Miyoshi myopathy.